期刊文献+

药源性血小板减少症的发生机制及诊断

Pathogenesis and diagnosis of drug-induced thrombocytopenia
下载PDF
导出
摘要 药源性血小板减少症(drug-induced thrombocytopenia,DITP)是临床最常见的一种继发性血小板减少症。根据血小板减少症的发病机制可分为2大类:非免疫介导和药源性免疫性血小板减少症(drug-induced immune thrombocytopenia,DIIT)。后者进一步根据不同的免疫介导作用机制划分为4类。除经典途径由药物依赖性血小板抗体(drug-dependent platelet-reactive antibodies,DDAbs)与血小板结合引起的DIIT、肝素诱导的血小板减少(heparin-induced thrombocytopenia,HIT)、免疫抑制剂诱导的血小板减少(immune checkpoint inhibitors-induced thrombocytopenia,ICI-ITP)以外,随着新型冠状病毒感染(COVID-19)后开展广泛疫苗研发及接种,新近出现的疫苗诱导的血栓性血小板减少(vaccine-induced thrombotic thrombocytopenia,VITT)也属于DITP范畴。本研究结合近年发表的相关文献,全面综述上述各类型DITP的发生机制特点及诊断,梳理DITP相关数据库,并提出未来研究展望。 Drug-Induced Thrombocytopenia(DITP)is the most common secondary thrombocytopenia in clinical practice.Based on the pathogenic mechanism,thrombocytopenia can be divided into two major categories:non-immune-mediated and drug-induced immune thrombocytopenia(DIIT).The latter is again classified into four categories based on different immune-mediated mechanisms.In addition to the classical pathway of drug-induced immune thrombocytopenia caused by drug-dependent platelet-reactive antibodies(DDAbs)binding to platelets,other categories include heparin-induced thrombocytopenia(HIT)and immune checkpoint inhibitors-induced thrombocytopenia(ICI-ITP).With the intensified development of vaccines and mass vaccinations following the global COVID-19 pandemic,a newly emerged category within DITP is vaccine-induced thrombotic thrombocytopenia(VITT).This article,in conjunction with related literature published in recent years,reviews the pathogenic characteristics and diagnosis of the aforementioned types of DITP,sorts out databases related to DITP and predicts the prospects of research.
作者 聂晓璐 马静瑶 孙凤 詹思延 NIE Xiaolu;MA Jingyao;SUN Feng;ZHAN Siyan(Center for Clinical Epidemiology&Evidence-based Medicine,Beijing Children‘s Hospital,Capital Medical University,National Center for Children’s Health,Beijing 100045,China;Department of Epidemiology and Biostatistics,School of Public Health,Peking University,Beijing 100091,China;Hainan Institute of Real World Data,Qionghai Hainan 571437,China;Department II of Hematology Center,Beijing Children’s Hospital,Capital Medical University,National Center for Children’s Health,Beijing 100045,China)
出处 《中国药物警戒》 2024年第7期829-835,共7页 Chinese Journal of Pharmacovigilance
基金 国家自然科学基金资助项目(82204149) 北京市医院管理中心“青苗”计划专项经费资助(QML20231204) 北京儿童医院科研苗圃计划(3-1-014-01-04) 海南博鳌乐城国际医疗旅游先行区真实世界研究专项计划项目(HNLC2022RWS012、HNLC2022RWS015)。
关键词 药源性血小板减少症 免疫性 半抗原 药物依赖性 肝素 疫苗 诱导 药品不良反应 drug-induced thrombocytopenia(DITP) immune drug-dependent antibodies heparin vaccine induced adverse drug reactions
  • 相关文献

参考文献3

二级参考文献60

  • 1白春梅,徐光勋,赵永强,韩少梅,单渊东.重组人血小板生成素治疗实体肿瘤患者化疗后血小板减少的多中心临床试验[J].中国医学科学院学报,2004,26(4):437-441. 被引量:37
  • 2华宝来,赵永强,朱铁楠,范连凯,王书杰,潘家绮.血小板减少患者皮下注射重组人血小板生成素后抗体生成的动态监测[J].血栓与止血学,2005,11(2):59-61. 被引量:16
  • 3方静,张荣艳,肖承京.白细胞介素11的细胞生物学作用及防治疾病的研究进展[J].实用临床医学(江西),2005,6(8):150-152. 被引量:15
  • 4万里新,单丽红,王旸,王文廉,蔡政,李琮宇.重组人白介素-11治疗恶性肿瘤放化疗后血小板减少28例[J].郑州大学学报(医学版),2007,42(5):966-967. 被引量:12
  • 5Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition[ J]. Br J Haematol, 2012,159 (5) :528-540.
  • 6Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J]. Chest, 2012,141(2 Suppl) :e495S-530S.
  • 7Beanverd Y, Boehlen F, Tessitore E, et al. Suspicion of heparin- induced thrombocytopcnia in internal medicine: How appropriate is the ordering of anti-PF4/heparin antibody testing? [ J ]. Platelets, 2015,26 ( 7 ) : 632-637.
  • 8Greinacher A, luhl D, Strobel U, et al. Heparin-induced thromboeytopenia: a prospective study on the incidence, platelet- activating capacity and clinical significance of antiplatelet factor 4/ heparin antibodies of the IgG, IgM, and IgA classes [ J ]. J Thromb Haemost, 2007,5 (8) : 1666-1673.
  • 9Blank M, Shoenfeld Y, Tavor S, et al. Anti-platclet factor 4/ heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells [ J ]. Int Immunol, 2002,14 ( 2 ) : 121-129.
  • 10Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach [ J ]. Semin Thromb Hemost, 2014, 40 ( 1 ) : 106-114.

共引文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部